Opendata, web and dolomites


A Unique Pancreatic Human Beta Cells to revolutionize the Diabetes Drug Discovery

Total Cost €


EC-Contrib. €






 BETASCREEN project word cloud

Explore the words cloud of the BETASCREEN project. It provides you a very rough idea of what is the project "BETASCREEN" about.

commercial    hope    line    tornell    predictive    avenues    generation    pharmas    cells    exceptional    outcome    beta    reproducibility    univercell    quantity    biotech    first    homogeneity    poor    coherence    rentability    decreasing    2015    issue    types    division    europe    industrial    human    patients    models    substitute    marketed    leader    accessible    pharma    ultimate    cell    jobs    industry    creation    15    selling    90    company    leaders    2021    regulatory    ub    pioneering    scarce    turnover    anti    betascreen    prevents    million    predictability    strategy    screening    academia    surprise    tissues    revenues    lack    market    innovative    disruptive    10    maturity    technologies    faced    generating    biosolutions    edge    accelerate    segments    ing    solution    population    secure    110    jan    samples    world    diabetes    1billion    clinical    saving    pharmaceutical    cutting    pressure    rate    portfolio    commercialization    think    adoption    strategic    industrials    attrition    replication    dollars    drug    animal    big    pancreatic    astrazeneca    stem    says    overcome    lines    bottlenecks   

Project "BETASCREEN" data sheet

The following table provides information about the project.


Organization address
postcode: 31000

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2017-01-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Univercell Biosolutions (UB) is a pioneering biotech company providing unique human cell models to accelerate and secure pharmaceutical products. UB is generating 1 M€ turnover in 2015 selling its first generation of human beta cell lines to 10 world pharma industry leaders. Pharmas rentability is decreasing facing to high regulatory pressure and low clinical predictability on human. The rate of clinical drug failure is about 90% and cost for marketed a new drug reach up to 1billion dollars. Early clinical predictability is a strategic issue for industrials. Jan Tornell an AstraZeneca division leader says: “The big think is that when we get into patients, we want no surprise”. Cells from human tissues samples are scarce and not accessible for Pharmas applications. Thus, Industrials developed substitute from animal with poor clinical predictability. Recently, Stem cell technologies has open new hope in providing large quantity of human cells but is still faced with major bottlenecks: lack of cell maturity (clinical predictability) and low cell population homogeneity (reproducibility) which prevents large adoption by industrials. UB has developed a portfolio of cutting edge technologies to overcome these bottlenecks. The first outcome of BETASCREEN is a disruptive pancreatic beta cell line for anti-diabetes research, with ultimate objective of replication to other cell types. The solution targets pharmaceutical, biotech, and academia. Within BETASCREEN, UB will define best commercialization strategy in coherence with market’s targeted segments and identify industrial partners for large-scale production (Phase 2) and commercialization. BETASCREEN will improve the predictive value of screening by decreasing the drug attrition rate up to 10%. Resulting cost saving for industrials could reach 100 million dollars per innovative new drug development. This will open exceptional commercial avenues for UB with revenues estimated at 15 M€ in 2021 and 110 jobs creation in Europe

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BETASCREEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BETASCREEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More